Biochemical and cellular aspects of the anticancer activity of selenium
- PMID: 2484522
- DOI: 10.1007/BF02990141
Biochemical and cellular aspects of the anticancer activity of selenium
Abstract
Aberrant differentiation is a frequent hallmark of tumors, suggesting that modulators for differentiation and proliferation play a role in multistage carcinogenesis and that their use can also be exploited in cancer chemoprevention and therapy. We have demonstrated that selenium (Se) may be a modulator for the differentiation and proliferation of tumor cells. Evidence has been obtained that Se exerts the following effects: reversing changes of biochemical phenotypes toward normal levels, including reduction of cGMP level and cAMP-dependent protein kinase isozyme type I; increase in cAMP level and cAMP-dependent protein kinase isozyme type II, and altering membrane properties. Furthermore, we have obtained support for this hypothesis utilizing experiments on cultured human liver cell lines. It is demonstrated that Se can lead to the following changes: a. reduction of mitotic index; b. increase in the adhesiveness of cells; c. decrease in confluent saturation density and induction of an early contact inhibition; and d. decrease in tumorigenicity. For the purpose of comparison, the effects of Se on the normal counterparts was also studied. Contrary to what was observed above, there was no significant change in both biochemical and cellular aspects of normal cells treated analogously.
Similar articles
-
[Level of cyclic AMP-dependent protein kinase isozyme in normal liver and hepatoma tissue and the effect of sodium selenite].Zhonghua Zhong Liu Za Zhi. 1986 Sep;8(5):339-41. Zhonghua Zhong Liu Za Zhi. 1986. PMID: 3568986 Chinese.
-
Study on the interaction of Se and erythrocyte membrane--effect of Se on the Na, K-ATPase activity and fluidity of erythrocyte membranes.Sci Sin B. 1986 Oct;29(10):1077-83. Sci Sin B. 1986. PMID: 3033820
-
Effects of cAMP and cGMP elevating agents on HL-60 cell differentiation.Pharmacol Toxicol. 1994 Aug;75(2):108-12. doi: 10.1111/j.1600-0773.1994.tb00331.x. Pharmacol Toxicol. 1994. PMID: 7971738
-
Up-regulation of the cAMP/PKA pathway inhibits proliferation, induces differentiation, and leads to apoptosis in malignant gliomas.Lab Invest. 1998 Feb;78(2):165-74. Lab Invest. 1998. PMID: 9484714 Review.
-
Selenium metabolism, selenoproteins and mechanisms of cancer prevention: complexities with thioredoxin reductase.Carcinogenesis. 1999 Sep;20(9):1657-66. doi: 10.1093/carcin/20.9.1657. Carcinogenesis. 1999. PMID: 10469608 Review.
Cited by
-
[Selenium in oncology. Really "noli nocere"?].Internist (Berl). 2003 Feb;44(2):227-9. doi: 10.1007/s00108-002-0837-9. Internist (Berl). 2003. PMID: 12674743 German. No abstract available.
-
Susceptibility of the antioxidant selenoenyzmes thioredoxin reductase and glutathione peroxidase to alkylation-mediated inhibition by anticancer acylfulvenes.Chem Res Toxicol. 2011 May 16;24(5):726-36. doi: 10.1021/tx2000152. Epub 2011 Apr 12. Chem Res Toxicol. 2011. PMID: 21443269 Free PMC article.
-
A preliminary report on the intervention trials of primary liver cancer in high-risk populations with nutritional supplementation of selenium in China.Biol Trace Elem Res. 1991 Jun;29(3):289-94. doi: 10.1007/BF03032685. Biol Trace Elem Res. 1991. PMID: 1726411 Clinical Trial.
-
Selenium. Mechanistic aspects of anticarcinogenic action.Biol Trace Elem Res. 1992 Apr-Jun;33:51-62. doi: 10.1007/BF02783992. Biol Trace Elem Res. 1992. PMID: 1379460 Review.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources